Gilead Sciences

Ted Love, MD, Joins Gilead Sciences’ Board of Directors

Retrieved on: 
Thursday, February 1, 2024
Biotechnology, Hospitals, Pharmaceutical, Health, Cardiology, Massachusetts General Hospital, Senior, Hospital, Spirit, Distinguished Service Award, MD, Research, Sickle cell disease, Science, Yale school, Patient, Genentech, Therapy, Gilead Sciences, Development, Biotechnology Innovation Organization, Onyx Pharmaceuticals, Internal medicine

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Ted Love, MD, has been appointed to the company’s Board of Directors.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Ted Love, MD, has been appointed to the company’s Board of Directors.
  • Dr. Love is currently chair of the Board of Directors of the Biotechnology Innovation Organization and serves on the Boards of Directors of Royalty Pharma and Structure Therapeutics.
  • “We are delighted to welcome Ted Love to the Gilead Board of Directors,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences.
  • Ted will be a valuable addition to the Gilead Board as we continue to expand our impact on patients and communities worldwide.”

Abdera Therapeutics Expands Management Team and Board of Directors

Retrieved on: 
Tuesday, January 30, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Sanofi, Pfizer, Neoplasm, National Cancer Institute, Science, Law, Novartis, Gorilla, Carcinoma, DLL3, Genentech, National Institutes of Health, Food, Therapy, Acquisition, Rest, Bangladesh Technical Education Board, Hematology, Princeton University, Gilead Sciences, University, Cancer, Internal medicine, SCB-2019, Pharmaceutical industry

“We are thrilled to welcome Philippe and Eric to Abdera,” said Lori Lyons-Williams, president and chief executive officer.

Key Points: 
  • “We are thrilled to welcome Philippe and Eric to Abdera,” said Lori Lyons-Williams, president and chief executive officer.
  • I am excited to join the Abdera team and help build a differentiated pipeline.”
    Mr. Dobmeier is an executive and board member with more than 20 years of experience in the biotechnology industry.
  • He currently serves on the boards of Structure Therapeutics and Atara Therapeutics.
  • “I look forward to working with the rest of the board and leadership team as Abdera prepares to transition into a clinical-stage company and enter its next phase of growth.”

Day One Announces Two New Appointments to Board of Directors

Retrieved on: 
Wednesday, January 17, 2024
Patient, Therapy, Medical college, Acceleron, Medical director, Hematology, Cancer, Microbiology, Gilead Sciences, Acquisition, Bayer, Cardiology, Neurology, AbbVie, Merck, Growth, Pharmaceutical industry

“We are excited to welcome Habib and Bill to our Board during this pivotal phase of our growth,” said Jeremy Bender, Ph.D., chief executive officer of Day One.

Key Points: 
  • “We are excited to welcome Habib and Bill to our Board during this pivotal phase of our growth,” said Jeremy Bender, Ph.D., chief executive officer of Day One.
  • “It’s a privilege to join the Board of Day One at such an important time,” said Habib Dable.
  • He currently sits on the Board of Directors for Pionyr Immunotherapeutics and Tizona Therapeutics, Inc., and the Oncology Advisory Board for Bryologyx.
  • I am grateful to join the Day One Board with my colleague Habib, and look forward to contributing to the evolution of the company.”

Gilead and Arcus Announce Amended Collaboration and Equity Investment

Retrieved on: 
Monday, January 29, 2024
Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Pancreatic cancer, Patient, Research, MD, Science, Partnership, Cancer, Lung cancer, NSCLC, CD73, Gilead Sciences, Safety, Gastrointestinal cancer, Doctor of Philosophy, TIGIT, Lung, Kidney cancer, Growth, Pharmaceutical industry

Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share.
  • The equity investment and collaboration amendment enable accelerated growth of the companies’ joint development programs that span multiple indications.
  • Additionally, Johanna Mercier, Chief Commercial Officer at Gilead Sciences, will join the Arcus Board, bringing Gilead’s total director designees to three.
  • The amendment also includes governance enhancements enabling streamlined decision-making and reflecting the continued growth of the collaboration.

Gilead and Arcus Announce Amended Collaboration and Equity Investment

Retrieved on: 
Monday, January 29, 2024
Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Pancreatic cancer, Patient, Research, MD, Science, Multimedia, Partnership, Cancer, Lung cancer, NSCLC, CD73, Gilead Sciences, Safety, Gastrointestinal cancer, Doctor of Philosophy, TIGIT, Lung, Kidney cancer, Growth, Pharmaceutical industry

Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share.
  • The equity investment and collaboration amendment enable accelerated growth of the companies’ joint development programs that span multiple indications.
  • Additionally, Johanna Mercier, Chief Commercial Officer at Gilead Sciences, will join the Arcus Board, bringing Gilead’s total director designees to three.
  • The amendment also includes governance enhancements enabling streamlined decision-making and reflecting the continued growth of the collaboration.

Los Angeles Blade to Celebrate 2024 ‘Best of LGBTQ Los Angeles’ Awards

Retrieved on: 
Friday, January 26, 2024
LGBTQ+, AIDS, Health, Communications, Consumer, Media, Publishing, Rhea, GLAAD, Christian Church, Los Angeles Pride, Multimedia, LGBTQ, Studio 54, Washington Blade, Pride parade, Out (magazine), Gay, Gilead Sciences, Metropolitan, HIV, Journalism, GLAAD Media Award, Nightclub

The Los Angeles Blade , LA’s only LGBTQ newspaper and nation’s only LGBTQ Media member of the White House Press Corps, partner newspaper of the venerable Washington Blade in DC, will present the 2024 Best Of LGBTQ Los Angeles Awards at Heart Weho on Saturday, January 27 from 8:00 p.m.

Key Points: 
  • The Los Angeles Blade , LA’s only LGBTQ newspaper and nation’s only LGBTQ Media member of the White House Press Corps, partner newspaper of the venerable Washington Blade in DC, will present the 2024 Best Of LGBTQ Los Angeles Awards at Heart Weho on Saturday, January 27 from 8:00 p.m.
  • In 2021, Los Angeles Blade publisher Troy Masters honored Los Angeles based philanthropist Ariadne Getty for her landmark donation to Gay Lesbian Alliance Against Defamation (GLAAD) community.
  • In 2022, the Los Angeles Blade honored David Geffen and presented him with the award.
  • With over 30 prestigious categories, the Los Angeles Blade “Best of LGBTQ LA” Awards will shine a spotlight on diverse stories and artists, activists and community notables and others who have championed critical LGBTQ issues and connected so powerfully with the community.

TransCelerate BioPharma Organized for Growth and Bringing New Innovation and Collaboration to the Biopharmaceutical R&D Community

Retrieved on: 
Wednesday, January 24, 2024
Biotechnology, Health, Science, Pharmaceutical, Research, Patient, Medicine, Data collection, Gilead Sciences, Drug development, Caregiver, Pharmaceutical industry

(TransCelerate), announced today an expansion of its membership and appointment of the organization’s Chief Operating Officer.

Key Points: 
  • (TransCelerate), announced today an expansion of its membership and appointment of the organization’s Chief Operating Officer.
  • Gilead Sciences, Inc. (Gilead), a leading biopharmaceutical company that has achieved breakthroughs in medicine for more than three decades, has joined TransCelerate as its newest member.
  • TransCelerate brings the global biopharmaceutical R&D community together, including some of the largest biopharmaceutical companies in the world, to accelerate and simplify the discovery and delivery of new medicines.
  • “TransCelerate has an unwavering commitment to foster collaboration across the biopharmaceutical R&D community.

Gilead Provides Update on Phase 3 EVOKE-01 Study

Retrieved on: 
Monday, January 22, 2024
Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Patient, Research, MD, Histology, ADC, Science, Survival, Docetaxel, Lung cancer, Immunotherapy, NSCLC, Gilead Sciences, Conference, Safety, Diarrhea, Doctor of Philosophy, Pembrolizumab, Lung, Pharmaceutical industry

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC).

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC).
  • A numerical improvement in OS favoring SG was observed in the study, including in patients with both squamous and non-squamous histology.
  • Based on strong preliminary efficacy and safety data from the Phase 2 EVOKE-02 study of Trodelvy in combination with pembrolizumab, presented at the World Conference on Lung Cancer 2023, Gilead remains confident in its ongoing Phase 3 EVOKE-03 study in 1L metastatic PD-L1 high NSCLC.
  • In addition, Gilead has a broad clinical development program in lung cancer with domvanalimab, the first Fc-silent investigational anti-TIGIT antibody.

Regenerative Medicine Market Worth $49.0 Billion | MarketsandMarkets™.

Retrieved on: 
Friday, January 26, 2024
Conditional sentence, Artificial intelligence, Dermatology, Market development, HSCT, Regenerative medicine, Research, Neurology, Pulse, Ophthalmology, Amgen, Smith & Nephew, Novartis, Cancer, Integration, Gilead Sciences, Investment, Tissue engineering, Takeda Pharmaceutical Company, Biogen, Transplant, Prevalence, DSM-IV codes, Growth, Veterinary medicine

The cell therapy segment accounted for the largest share of the regenerative medicine market in 2022.

Key Points: 
  • The cell therapy segment accounted for the largest share of the regenerative medicine market in 2022.
  • In 2022, the musculoskeletal disorders segment accounted for the largest share of the global regenerative medicine market.
  • •  Market Development: Comprehensive information about lucrative markets – the report analyses the regenerative medicine market across varied regions.
  • •  Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the regenerative medicine market.

Non-Alcoholic Steatohepatitis Treatment Drug Market In Japan is Expected to Showcase Impressive Growth by 2032 | DelveInsight

Retrieved on: 
Wednesday, January 17, 2024
Obesity, Merck & Co., MRI, LAS, Weight loss, Fatty liver disease, Type 2 diabetes, Magnetic resonance imaging, Insulin resistance, NASH, FFAR4, Liver, Liver disease, Diabetes, Alcoholic liver disease, Therapy, Hypertension, PPAR, Eli Lilly and Company, Gilead Sciences, Chronic pain, Disease, Inflammation, FASN, AstraZeneca, Novo Nordisk, FXR, Prevalence, CCR5, FGF, Physical examination, Weakness, Bronchial thermoplasty, Cilofexor, Metabolic syndrome, Mitsubishi Tanabe Pharma, Development, NAFLD, Risk, Fibrosis, Fatigue, Dyslipidemia, USD, Non-alcoholic fatty liver disease, Merck, Pharmaceutical industry

LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.

Key Points: 
  • LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.
  • According to DelveInsight's analysis, the market size for NASH reached USD 200 million in 2022 in Japan and is expected to grow with a significant CAGR by 2032.
  • DelveInsight's analysis reveals that the overall diagnosed prevalent population of NASH in Japan was reported as 2.5 million in 2022.
  • Among the forecasted emerging therapies, MGL-3196 (Resmetirom) is expected to capture the highest market in Japan by 2032.